Literature DB >> 32209352

Characterization of serum levels of testosterone and corticosterone in a blast and amputation rat model of heterotopic ossification.

Mack Y Qin1, Rex E Atwood1, William A Ketchum2, Stephen A Kaba3, Matthew J Bradley1.   

Abstract

INTRODUCTION: Endocrine dysregulation's role in heterotopic ossification (HO) remains unexplored. We sought to examine corticosterone and testosterone in established rat models of ectopic bone formation, and correlate to HO formation with CT analysis.
METHODS: Fifteen rats were placed into three groups of traumatic injury patterns: Blast and injury (120 kPa blast, femoral fracture and quadriceps crush), injury only, and blast only. Serum corticosterone and testosterone levels were drawn until post-operative day 40. HO was analyzed using CT.
RESULTS: Corticosterone levels peaked in the blast and injury group in the shortest time post injury, followed by injury only and blast only groups. Testosterone levels reached nadir in similar fashion. Volume of HO was highest in the blast and injury group, followed by the injury only group.
CONCLUSION: Corticosterone and testosterone's contribution to HO formation requires further characterization, but this study suggests that high peaks in corticosterone and a low nadir in testosterone are associated with higher volumes of HO.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amputation; Blast; Corticosterone; Heterotopic ossification; Testosterone; Trauma

Mesh:

Substances:

Year:  2020        PMID: 32209352     DOI: 10.1016/j.mce.2020.110799

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  1 in total

1.  Development of a rodent high-energy blast injury model for investigating conditions associated with traumatic amputations.

Authors:  Zepur Kazezian; Xiancheng Yu; Martin Ramette; Warren Macdonald; Anthony M J Bull
Journal:  Bone Joint Res       Date:  2021-03       Impact factor: 5.853

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.